1-day HTA Scientific Meeting, Actelion, June 23, 2015

Time	Topic	Presenter
9:30	Welcome	
	Session: Trends in HTA	
9:40-10:30	*IMI GetReal Initiative Update*	Chrissie Fletcher (Amgen) Matthias Egger (Univ. of Bern)
10:30-11:00	*Expert panel discussion on trends and burning issues, eg. Structured benefit risk and real world evidence; dual EMA-HTA consultation*	Invited Panelists (TBC): Ansgar Hebborn (Roche) Marie-Ange Paget (Lilly) Richard Nixon (Novartis) Thomas Cueni (InterPharma) Moderator: Fred Sorenson (Xcenda)
11:00-11:30	BREAK	
	Session: Use of HTA for Medical Devices and Diagnostics	
11:30-12:00	*Overview of HTA for medical devices and diagnostics*	Pascale Brasseur (Medtronic)
12:00-12:30	*NICE's approach to the development of guidance for medical devices and diagnostics*	Sheryl Warttig (NICE)
12:30-13:00	*EUnetHTA core model applied to Colorectal Cancer screening*	Karsten Berndt (Roche Diagnostics)
13.00-14.00	LUNCH	
	Session: Application of Methods & Analysis Challenges (1)	
14:00-14:30	*Uses of Social Media for Outcomes Research – results of a real-world pilot*	Valéry Risson (Novartis)
14:30-15:00	*Adjusting overall survival for treatment switch/crossover*	Claire Watkins (AstraZeneca)
15:00-15:30	*Using the EUnetHTA HTA core model as a framework for planning, generating and presenting evidence*	Pierre Ducournau (Roche)
15:30-15:50	BREAK	
	Session: Application of Methods & Analysis Challenges (2)	
15:50-16:20	*Predicting long term survival using nonparametric Bayesian methods: the melanoma case*	Yovanna Castro (Roche)
16:20-16:50	*Reimbursement challenges with new emerging cancer therapies*	Nathalie Barbier (Novartis)
16:50-17:20	*The value of Oncology therapies and emerging access hurdles in Canada and the United States*	Won Lee (Xcenda)
17.20-17.30	Summary and meeting close	